1.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: CALGB-80101, NCCTG-CALGB-80101, ECOG-CALGB-80101, NCT00052910
|
|
2.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: RTOG-0436, RTOG 0436, NCT00655876
|
|
3.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 85
Sponsor: Other
Protocol IDs: 0806009855, NCT00760604
|
|
4.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: AT-101-CS-102, NCT00561197
|
|
5.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 82
Sponsor: Other
Protocol IDs: Pro00002207, SPS 151596, NCT00578071
|
|
6.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: 07326, NCT00667420
|
|
7.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 12652A, NCT00203905
|
|
8.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: CALGB-80302, NCT00316862
|
|
9.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: MSKCC-06013, NCT00354679
|
|
10.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: SCRI GI 91, AVF3921s, NCT00393068
|
|
11.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 80
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: JHOC-J0386, J0386, JHOC-04-02-20-03, ZENECA-IRUSIRES0304, NCT00493025
|
|
12.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Over 65
Sponsor: NCI
Protocol IDs: RPCI-I-62705, I 62705, NCT00524121
|
|
13.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: BrUOG-E-215, NCT00522795
|
|
14.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 75 and under
Sponsor: Other
Protocol IDs: 2003-0769, NCT00525785
|
|
15.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: 2004-0703, NCT00525915
|
|
16.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: UMCC 2006.117, NCT00570531
|
|
17.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: PR016-CLN-pro003, NCT00573131
|
|
18.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: Over 18
Sponsor: NCI
Protocol IDs: CASE-2Y07, CASE2Y07, NCT00601705
|
|
19.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: ACOSOG-Z4051, Z4051, NCT00757172
|
|
20.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NU-0512, NU 05I2, NU-IRB-0948-009, NCT00711412
|
|
21.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 1399-05, CA111603-01A1, NCT00217087
|
|
22.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: DMS-9939, NCI-G01-1931, NCT00014417
|
|
23.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 2008_541, V934-002, NCT00753415
|
|
24.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: NYU 05-409, NCT00821652
|
|
25.
|
Phase: No phase specified
Type: Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 99-0522, NCT00260559
|
